But you cannot fail early if you cannot see risk clearly. Drug development still relies heavily on sequential experimentation ...

Revolution Medicines thinks it could transform the treatment of pancreatic cancer – one of the hardest forms to treat – based ...

Hemab Therapeutics, chaired by former Alnylam chief executive John Maraganore, has published its redacted IPO prospectus with ...

In our penultimate video from this year’s LSX World Congress, web editor Nicole Raleigh spoke with Mike Cooke, CEO of AmacaThera, a leading developer of next-generation hydrogel-based drug delivery ...

AI algorithms that can identify which patients are most likely to benefit from a drug recently backed for NHS use as a colorectal cancer (CRC) therapy have been developed by scien ...

Servier $210 million bet on IDEAYA's uveal melanoma therapy darovasertib seems to have paid off, as the drug has hit the mark in a phase 2/3 that could form the basis of regulatory filings later this ...

The phase 1 BEHOLD-1 trial of B7-H4-directed mocertatug rezetecan (Mo-Rez, formerly HS-20093) showed an objective response rate (ORR) of 62% in platinum-resistant ovarian cancer (PROC) and 67% in ...

AstraZeneca's Lokelma therapy for high potassium levels in the blood (hyperkalaemia) should see much wider usage by the NHS after becoming one of the first medicines to be assessed under NICE's raised ...

Novo Nordisk has agreed to buy Akero Therapeutics and its drug candidate for metabolic dysfunction-associated steatohepatitis (MASH) for $4.7 billion upfront, shortly after claiming FDA approval to ...

From Eli Lilly revealing its fourth new manufacturing site in a $27 billion capital investment spree in the US – a $3.5 billion facility in Lehigh Valley, Pennsylvania – to the FDA starting to accept ...

Replimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, a decision that has led the company to accuse the agency of inconsistencies in its review of the drug.

The FDA has approved orforglipron, under the Foundayo trade name, in just 50 days, thanks to a fast track review under the ...